Form 4: Director Beverly Huss Granted RBOT Stock Options

Vicarious Surgical Inc. Director Beverly Huss was granted 5,335 stock options with an exercise price of $7.61, vesting on June 27, 2026, or prior to the next annual meeting.

Summary

• Beverly A. Huss, a Director of Vicarious Surgical Inc. (RBOT), was granted 5,335 stock options.
• The options have an exercise price of $7.61 per share.
• The grant date for these options was June 27, 2025.
• The options are for Class A Common Stock and expire on June 26, 2035.
• The shares underlying these options will vest on June 27, 2026, or one day prior to the Issuer's next Annual Meeting of Shareholders, whichever is earlier.
• Vesting is contingent upon Ms. Huss's continued service through the applicable vesting date.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine compensation event, generally viewed as neutral to slightly positive as it aligns interests, but does not indicate significant operational or financial news.

Positives

• The grant of stock options aligns the director's interests with shareholder value, incentivizing long-term performance.
• The options have a 10-year expiration period, providing a long window for potential value realization.

Negatives

• The exercise price of $7.61 is a hurdle that the stock price must exceed for the options to have intrinsic value.

Risks

• The options' value is subject to the future performance of Vicarious Surgical Inc.'s stock price.
• Vesting is conditional on the director's continued service, meaning the options could be forfeited if service ceases before the vesting date.

Future Outlook

The options are set to vest on June 27, 2026, or one day prior to the Issuer's next Annual Meeting of Shareholders, whichever is earlier, subject to continued service. This indicates a future milestone for the director's compensation.

Industry Context

This filing is a standard disclosure of director compensation in the form of equity, common across publicly traded companies in all industries, including the medical technology or robotics sector where Vicarious Surgical operates. It does not provide specific industry trends.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially encouraging decisions that enhance long-term stock value.

Next Steps

• The stock options will vest on June 27, 2026, or one day prior to the Issuer's next Annual Meeting of Shareholders, whichever is earlier, provided the director continues service.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a director and does not contain information significant enough to warrant a change in investment recommendation. It is a standard disclosure that aligns director incentives with shareholder value but provides no new fundamental insights into the company's operational or financial performance.

Keywords

Vicarious Surgical, RBOT, Stock Options, Form 4, Director Compensation, Equity Grant, Insider Transaction, Beverly Huss